Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new small ...

We came across a bullish thesis on Eli Lilly and Company on Stock Analysis Compilation’s Substack. In this article, we will ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Pfizer, Inc. (NYSE:PFE) is one of the high-margin pharma stocks to buy now. Bristol-Myers Squibb Company (NYSE:BMY) and Pfizer, Inc.

Eli Lilly faces a pivotal moment as its stock experiences a slight pullback. Investors are eyeing its upcoming earnings ...